Summary
- Terns Pharmaceuticals, Inc. stock has surged 770% YTD, driven by strong TERN-701 data in chronic myeloid leukemia, or CML, the latest outstanding …
Summary
- Terns Pharmaceuticals, Inc. stock has surged 770% YTD, driven by strong TERN-701 data in chronic myeloid leukemia, or CML, the latest outstanding data set shared yesterday.
- TERN-701 demonstrated superior major molecular response rates versus Novartis’ Scemblix, with robust safety and efficacy in heavily pre-treated CML patients.
- Management is prioritizing TERN-701, raising $400M for pivotal studies, with Phase 3 initiation and regulatory milestones as key upcoming catalysts.
- With a $3.86B market cap, ample cash, and potential M&A interest, TERN stock remains a high-upside, high-conviction biotech play.
Dougal Waters/DigitalVision via Getty Images
Investment Overview
Back in July, in a note for Seeking Alpha, I suggested that Terns Pharmaceuticals, Inc. (TERN) stock was a "risky buy ahead of Q4 Obesity, Oncology Catalysts."
It’s been my best call
This article was written by
14.42K Followers
**Analyst’s Disclosure:**I/we have a beneficial long position in the shares of BMY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.